Xarelto & Pradaxa Manufacturers Spent Millions Bribing Doctors
Pharmaceutical companies are spending millions of dollars marketing blood-thinners like Xarelto and Pradaxa to doctors. ABC investigation found that manufacturers such as Bayer and Boehringer Ingelheim spend almost $3 million on “educational events” for doctors in a six-month period in 2015. This is troublesome since concerns are mounting that these potentially dangerous medications are being
Read More
New Study Suggests Xarelto Causes More Bleeding Than Even Pradaxa
A study published in JAMA Internal Medicine suggests Xarelto causes more bleeding than Pradaxa. Researchers found that people using Xarelto may be more likely to have a serious bleeding event than those taking Pradaxa. This could explain why manufacturer, Johnson & Johnson is facing close to 20,000 Xarelto lawsuits. JAMA Study: Xarelto Causes More Bleeding Researchers
Read More
Xarelto Tested For New Use
The dangerous blood thinner, Xarelto headed for a new use. Manufacturer, Janssen announced they would be stopping their COMPASS trial a year early. This trial is part of their Explorer research program to expand Xarelto to 10 more label uses. COMPASS trial was evaluating the efficacy and safety of the blood thinner for the prevention
Read More
Xarelto May Cause Dementia in AFib Patients
This is Michael Brady Lynch, Lead Trial Attorney for the Michael Brady Lynch Firm. Researchers at the Intermountain Medical Center Heart Institute published a study warning people with the heart rhythm disorder atrial fibrillation (AFib) that they may have a heightened risk of developing dementia while taking clot-preventing drugs like Xarelto. The study researched over 6,000
Read More
Xarelto Approval Trial Skewed by Faulty Blood Monitor
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. In a dramatic turn of events in the sordid saga of the drug Xarelto, the FDA is now questioning the very approval data behind Xarelto’s claims as a miracle drug. Information has surfaced that is leading the FDA to re-examine the
Read MoreCorporate Greed and the Saga of Xarelto and Pradaxa
“Why are Xarelto and Pradaxa still on the market?” The only true answer is corporate greed. As long as these pharmaceutical corporations keep making billions in drug sales, they will disregard the inconceivable risks. These risks bring real injuries to consumers caused by dangerous drugs. It is disheartening to see TV advertisements of these dangerous
Read More